[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455097-105":59,"doc-detail-455097-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mavacamten-in-hypertrophic-obstructive-cardiomyopathy-with-hepato-renal-comorbidities-a-case-report","Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities - A case report","","Rationale: Mavacamten is an innovative drug for hypertrophic obstructive cardiomyopathy (HOCM) that improves cardiac function by reducing left ventricular outflow tract obstruction, yet safety data in patients with liver and kidney impairment remain limited. Patient concerns: A 68-year-old man with HOCM, heart failure, gout, and chronic kidney and liver impairment was hospitalized for worsening heart failure and upper gastrointestinal bleeding. After starting mavacamten 2.5 mg daily, NYHA class improved from III to I-II, LVOTG decreased from 105 to 16 mm Hg, and liver and kidney functions stayed stable. The case underscores individualized, multidisciplinary management in multiorgan comorbidity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mavacamten-in-hypertrophic-obstructive-cardiomyopathy-with-hepato-renal-comorbidities-a-case-report/455097/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mavacamten-in-hypertrophic-obstructive-cardiomyopathy-with-hepato-renal-comorbidities-a-case-report/455097.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of using mavacamten in this case?","Question",{"text":113,"@type":114},"Mavacamten is used to reduce left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy, improving overall cardiac function.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which patient-related comorbidities complicated management?",{"text":118,"@type":114},"The patient had chronic kidney disease stage IIIB, hepatic schistosomiasis with portal hypertension and splenomegaly, gout with tophaceous deposits, and moderate anemia along with upper GI bleeding.",{"name":120,"@type":111,"acceptedAnswer":121},"What treatment outcome was reported after starting mavacamten?",{"text":122,"@type":114},"NYHA class decreased from III to I-II and LVOTG fell from 105 to 16 mm Hg, while liver and kidney function remained stable during treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},455097,1791036364,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","®  \n Clinical Case Report   \nMavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities A case report  \nLiping Ma, MMa ,* , Fengqin Li, MMb , Sophia Dongc , Rongrong Li, MMb  \n\n| Abstract\u003Cbr>Rationale: Mavacamten is an innovative drug for hypertrophic obstructive cardiomyopathy (HOCM) . It improves cardiac function by reducing left ventricular outflow tract obstruction. However, safety data in patients with liver and kidney impairment are limited. Patient concerns: A 68-year-old man was admitted with a history of HOCM, heart failure, gout, and chronic kidney and liver impairment. He was admitted because of worsening heart failure symptoms and an episode of upper gastrointestinal bleeding. The combined burden of these illnesses significantly impaired his ability to perform daily activities independently, leading to hospitalization for optimized management of his advanced cardiac disease.\u003Cbr>Diagnoses: Hypertrophic obstructive cardiomyopathy (apical aneurysm, post-cardiac resynchronization therapy), New York Heart Association class III. Hepatic schistosomiasis with portal hypertension, splenomegaly, upper GI bleeding, moderate anemia. Chronic gout with tophaceous deposits. Chronic kidney disease stage IIIb.\u003Cbr>Interventions: Initiated mavacamten 2.5 mg once daily for severe left ventricular outflow tract obstruction refractory to maximally tolerated beta-blockers.\u003Cbr>Outcomes: The patient showed significant improvement after treatment. The New York Heart Association class decreased from III to I-II, and the LVOTG dropped from 105 to 16 mm Hg. Meanwhile, liver and kidney functions remained stable during the course of treatment.\u003Cbr>Lessons: This case highlights the complexity of managing HOCM with multiorgan comorbidities, emphasizing the role of novel therapies (e.g. , mavacamten) in refractory outflow obstruction and the need for tailored multidisciplinary approaches. Abbreviations: CYP = cytochrome pathway, HOCM = hypertrophic obstructive cardiomyopathy, IVSd = interventricular septal thickness, LVEF = left ventricular ejection fraction, LVOTG = left ventricular outflow tract pressure gradient, LVOTO = left ventricular outflow tract obstruction, SAM = systolic anterior motion. |\n| --- |\n| Keywords: chronic kidney disease, cirrhosis, hypertrophic cardiomyopathy, individualize therapy, mavacamten |\n\n1. Introduction  \nHypertrophic obstructive cardiomyopathy (HOCM), a common genetic cardiac disorder, is characterized by mutations in myocardial sarcomere protein genes that disrupt cardiomyocyte alignment and cause asymmetric ventricular wall thickening, ultimately leading to left ventricular outflow tract obstruction (LVOTO) . This pathophysiological process manifests clinically through exertional dyspnea, chest pain, and syncope, with severe cases progressing to end-stage heart  \nfailure or sudden cardiac death. [1] Diagnosis primarily relies on echocardiography, which reveals hallmark features including increased interventricular septal thickness (≥15 mm in adults) and elevated left ventricular outflow tract pressure gradient (LVOTG) (≥30 mm Hg at rest or ≥ 50 mm Hg with provocation) . [2] Additional diagnostic criteria encompass systolic anterior motion of the mitral valve and dynamic LVOTO exacerbated by reduced ventricular preload or increased contractility. Currently, therapeutic strategies have evolved into 3  \nThe patient parents provided written informed consent for the publication of any associated data and accompanying images.  \nThe authors have no conflicts of interest to disclose.  \nThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.  \nAll procedures involving the participant in this case report followed the ethical standards of the institutional committees and Declaration of Helsinki. Informed consent was obtained from the patient. This study was approved by the Ethics Committee of the Research Ethics Commit","cbCaibe5HXAHgSpX","https://ap.wps.com/l/cbCaibe5HXAHgSpX","pdf",766124,"English","# Introduction\n## Diagnosis and clinical features\n## Diagnostic criteria and current therapies\n## Case presentation and outcomes","[{\"question\":\"What is the main purpose of using mavacamten in this case?\",\"answer\":\"Mavacamten is used to reduce left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy, improving overall cardiac function.\"},{\"question\":\"Which patient-related comorbidities complicated management?\",\"answer\":\"The patient had chronic kidney disease stage IIIB, hepatic schistosomiasis with portal hypertension and splenomegaly, gout with tophaceous deposits, and moderate anemia along with upper GI bleeding.\"},{\"question\":\"What treatment outcome was reported after starting mavacamten?\",\"answer\":\"NYHA class decreased from III to I-II and LVOTG fell from 105 to 16 mm Hg, while liver and kidney function remained stable during treatment.\"}]","Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities - A case report | PDF",1790742108,13]